ProCE Banner Activity

Myelofibrosis: Emerging Therapeutic Strategies and Managing Patients Intolerant/Resistant to Ruxolitinib

Slideset Download
Download this slideset for expert perspectives on emerging therapies and optimal management of patients with myelofibrosis that is intolerant/resistant to ruxolitinib.

Released: December 06, 2019

Expiration: December 04, 2020

Share

Faculty

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

CTI BioPharma Corp., a Sobi Company

Geron

Faculty Disclosure

Primary Author

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York